TNF-α is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage

Journal of Neuroimmunology

Volumn 182, Issue 1-2, 2007, Pages 73-79

  Vinores, Stanley A ^a   Xiao, Wei Hong ^a   Shen, JiKui ^a   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood retinal barrier; Interleukin 1 ; Leukostasis; Platelet activating factor; Retinal neovascularization; Tumor necrosis factor ; Vascular endothelial growth factor

Indexed keywords

INTERLEUKIN 1BETA; OXYGEN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ISCHEMIC RETINOPATHY; LEUKOCYTE; LEUKOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETINOPATHY; WILD TYPE;

ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; INTERLEUKIN-1BETA; ISCHEMIA; LEUKOSTASIS; MICE; MICE, KNOCKOUT; OXYGEN; PLATELET ACTIVATING FACTOR; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846016638     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.09.015     Document Type: Article

References (44)

1. Adamis A.P., Miller J.W., Bernal M.-T., D'Amico D.J., Folkman J., Yeo T.-K., and Yeo K.-T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118 (1994) 445-450
2. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen M.S., Aiello L.M., Ferrara N., and King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331 (1994) 1480-1487
3. Armstrong D., Ueda T., Ueda T., Aljada A., Browne R., Fukuda S., Spengler R., Chou R., Harnett M., Buch P., Dandona P., Sasisekharan R., and Dorey C.K. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor, and platelet-derived growth factors. Angiogenesis 1 (1998) 93-104
4. Borsi L., Balza E., Carnemolla B., Sassi F., Castellani P., Berndt A., Kosmehl H., Biro A., Siri A., Orecchia P., Grassi J., Neri D., and Zardi L. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102 (2003) 4284-4392
5. Campochiaro P.A. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest. Ophthalmol. Visual Sci. 47 (2006) 462-474
6. Camussi G., Albano E., Tetta C., and Bussolino F. The molecular action of tumor necrosis factor-alpha. Eur. J. Biochem. 202 (1991) 3-14
7. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 72 (1975) 3666-3670
8. Clauss M., Sunderkotter C., Sveinbjornsson B., Hippenstiel S., Willuweit A., Marino M., Hass E., Seljelid R., Scheurich P., Suttorp N., Grell M., and Risau W. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97 (2001) 1321-1329
9. Derevjanik N.L., Vinores S.A., Xiao W.-H., Mori K., Turon T., Hudish T., Dong S., and Campochiaro P.A. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest. Ophthalmol. Visual Sci. 43 (2002) 2462-2467
10. Fajardo L.F., Kwan H.H., Kowalski J., Prionas S.D., and Allison A.C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol. 140 (1992) 539-544
11. Frater-Schroder M., Risau W., Hallmann R., Gautschi P., and Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5277-5281
12. Gardiner T.A., Gibson D.S., de Gooyer T.E., de la Cruz V.F., McDonald D.M., and Stitt A.W. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am. J. Pathol. 166 (2005) 637-644
13. Giraudo E., Primo L., Audero E., Gerber H.-P., Koolwijk P., Soker S., Klagsbrun M., Ferrara N., and Bussolino F. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J. Biol. Chem. 273 (1998) 22128-22135
14. Grell M., Zimmermann G., Hulser D., Pfizenmaier K., and Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J. Immunol. 153 (1994) 1963-1972
15. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Yung S., Chimenti S., Landsman L., Abramaovitch R., and Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
16. Hangai M., He S., Hoffmann S., Lim J.I., Ryan S.J., and Hinton D.R. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J. Neuroimmunol. 171 (2006) 45-56
17. Hsu H., Shu H.B., Pan M.G., and Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interaction define two distinct TNF receptor 1 signaling pathways. Cell 84 (1996) 299-308
18. Ilg R.C., Davies M.H., and Powers M.R. Altered retinal neovascularization in TNF receptor-deficient mice. Curr. Eye Res. 30 (2005) 1003-1013
19. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Miller J.W., Gragoudas E.S., Ng Y.S., D'Amore P.A., Shima D.T., and Adamis A.P. VEGF 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198 (2003) 483-489
20. Joussen A.M., Murata T., Tsujikawa A., Kirchhof B., Bursell S.-E., and Adamis A.P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol. 158 (2001) 147-152
21. Kahn P., Weiss M., Imundo L.F., and Levy D.M. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113 (2006) 860-864
22. Lang R.A., and Bishop M.J. Macrophages are required for cell death and tissue remodeling in the developing mouse eye. Cell 74 (1993) 453-462
23. Lienard D., Ewalenko P., Delmotte J.J., Renard N., and Lejeune F.J. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10 (1992) 52-60
24. Limb G.A., Chignall A.H., Green W., LeRoy F., and Dumonde D.C. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br. J. Ophthalmol. 80 (1996) 168-173
25. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., and van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br. J. Ophthalmol. 89 (2005) 533-566
26. Luna J.D., Chan C.C., Derevjanik N.L., Mahlow J., Chiu C., Peng B., Tobe T., Campochiaro P.A., and Vinores S.A. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J. Neurosci. Res. 49 (1997) 268-280
27. Majka S., McGuire P.G., and Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest. Ophthalmol. Visual Sci. 43 (2002) 260-266
28. Mauceri H.J., Hanna N.N., Wayne J.D., Hallahan D.E., Hellman S., and Weichselbaum R.R. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56 (1996) 4311-4314
29. Miller J.W., Adamis A.P., Shima D.T., D'Amore P.A., Moulton R.S., O'Reilly M.S., Folkman J., Dvorak H.F., Brown L.F., Berse B., Yeo T.-K., and Yeo K.-T. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145 (1994) 574-584
30. Nabors L.B., Suswam E., Huang Y., Yang X., Johnson M.J., and King P.H. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res. 63 (2003) 4181-4187
31. Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., Sugita S., Ueno S., Yoshizaki K., and Inaba G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J. Rheumatol. (2004) 1362-1368
32. Old L.J. Tumor necrosis factor (TNF). Science 230 (1985) 630-632
33. Ozaki H., Seo M.-S., Ozaki K., Yamada H., Yamada E., Hofmann F., Wood J., and Campochiaro P.A. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156 (2000) 679-707
34. Paparakis M., Alexopoulou L., Episkopou V., and Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and the maturation of the humoral immune response. J. Exp. Med. 184 (1996) 1397-1411
35. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., and Smith L.E.H. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 905-909
36. Rosenbaum J.T., Howes E.L.J., Rubin R.M., and Samples J.R. Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am. J. Pathol. 133 (1988) 47-53
37. Smith L.E.H., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., and D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Visual Sci. 35 (1994) 101-111
38. Song H.Y., Regnier C.H., Kirschning C.J., Goeddel D.V., and Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9792-9796
39. Tartaglia L.A., Ayres T.M., Wong G.H., and Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74 (1993) 845-853
40. Tobe T., Okamoto N., Vinores M.A., Derevjanik N.L., Vinores S.A., Zack D.J., and Campochiaro P.A. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest. Ophthalmol. Visual Sci. 39 (1998) 180-188
41. Tobe T., Ortega S., Luna J.D., Ozaki H., Okamoto N., Derevjanik N.L., Vinores S.A., Basilico C., and Campochiaro P.A. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 153 (1998) 1641-1646
42. Tsuchihashi S., Ke B., Kaldas F., Flynn E., Busuttil R.W., Briscoe D.M., and Kupiec-Weglinski J.W. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am. J. Pathol. 168 (2006) 695-705
43. Yamada H., Yamada E., Ando A., Esumi N., Bora N., Saikia J., Sung C.-H., Zack D.J., and Campochiaro P.A. FGF2 decreases hyperoxia-induced cell death in mice. J. Am. Pathol. 159 (2001) 1113-1120
44. Yoshida S., Ono M., Shono T., Izumi H., Ishibashi T., and Suzuki H. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol. 17 (1997) 4015-4023